Pyrros Papakostas1, Georgia Tsaousi2, George Stavrou2, Dimitrios Rachovitsas3, Gavriil Tsiropoulos3, Constantina Rova3, Ioannis Konstantinidis3, Antonios Michalopoulos2, Vasilios Grosomanidis2, Katerina Kotzampassi4. 1. Endoscopy Unit, Department of Surgery, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece. 2. Department of Surgery, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece. 3. Department of Otorhinolaryngology - Head and Neck Surgery, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece. 4. Endoscopy Unit, Department of Surgery, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece; Department of Surgery, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece. Electronic address: kakothe@yahoo.com.
Abstract
OBJECTIVES: Head and neck cancer patients commonly suffer from severe malnutrition at the time of tentative diagnosis. Percutaneous Endoscopic Gastrostomy [PEG] feeding is now considered as an efficient tool to reduce nutritional deterioration alongside concurrent treatment. We undertook the challenge to retrospectively evaluate the impact of a commercial, disease-specific, feeding formula [Supportan, Fresenius Kabi, Hellas] versus blenderized family food on nutritional outcome. MATERIALS AND METHODS: This is a retrospective analysis of prospectively collected nutritional and anthropometric data at the time of PEG placement, at the 8th week [after treatment termination] and at 8 months [6mo of recovery from treatment]. All patients were prescribed a commercial feeding formula. RESULTS: The final dataset included 212 patients: 112 received the commercial formula, 69 voluntarily decided to switch into blenderized-tube-feeding, and 31 were prescribed to receive a home-made formula of standard ingredients. The commercial formula seemed to help patients to fight the catabolism of concurrent treatment, since, at the 8mo assessment, both Body Mass index and Fat Free Mass had almost recovered to the values at the time of first diagnosis. Neither group on blenderized or home-made formulas exhibited nutritional improvement, but experienced a significant deterioration throughout the study period, with the home-made formula group being the worst. CONCLUSION: These findings clearly indicate that home-made and blenderized foods do not adequately support the nutritional requirements of patients with HNC scheduled to receive concurrent CRT treatment.
OBJECTIVES: Head and neck cancerpatients commonly suffer from severe malnutrition at the time of tentative diagnosis. Percutaneous Endoscopic Gastrostomy [PEG] feeding is now considered as an efficient tool to reduce nutritional deterioration alongside concurrent treatment. We undertook the challenge to retrospectively evaluate the impact of a commercial, disease-specific, feeding formula [Supportan, Fresenius Kabi, Hellas] versus blenderized family food on nutritional outcome. MATERIALS AND METHODS: This is a retrospective analysis of prospectively collected nutritional and anthropometric data at the time of PEG placement, at the 8th week [after treatment termination] and at 8 months [6mo of recovery from treatment]. All patients were prescribed a commercial feeding formula. RESULTS: The final dataset included 212 patients: 112 received the commercial formula, 69 voluntarily decided to switch into blenderized-tube-feeding, and 31 were prescribed to receive a home-made formula of standard ingredients. The commercial formula seemed to help patients to fight the catabolism of concurrent treatment, since, at the 8mo assessment, both Body Mass index and Fat Free Mass had almost recovered to the values at the time of first diagnosis. Neither group on blenderized or home-made formulas exhibited nutritional improvement, but experienced a significant deterioration throughout the study period, with the home-made formula group being the worst. CONCLUSION: These findings clearly indicate that home-made and blenderized foods do not adequately support the nutritional requirements of patients with HNC scheduled to receive concurrent CRT treatment.
Authors: Amy Y Spurlock; Teresa W Johnson; Ali Pritchett; Leah Pierce; Jenna Hussey; Kelly Johnson; Holly Carter; Stephen L Davidson; Manpreet S Mundi; Lisa Epp; Ryan T Hurt Journal: Nutr Clin Pract Date: 2021-08-31 Impact factor: 3.204